Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

A pair of studies show that Zepbound can help adults with obesity and overweight achieve sustained and meaningful weight loss ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...

Eli Lilly on Thursday reported promising results for a daily pill that could serve as an alternative to injectable ...

Eli Lilly shares are now positive for the year, up 10% since the start of January.

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Meta c Mark Zuckerberg took the stand on Monday in a historic antitrust trial that could force the tech giant to break off ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...